We’ve heard about the promise of cancer immunotherapy and in particular checkpoint inhibitors, but not everyone responds. It’s typically around 25-30% in most cancers.
So how do we identify those patients that are likely to respond, and perhaps more importantly, how can we increase the percentage of patients that do respond?
Immune biomarkers are key to answering both those questions, and understanding the rationale for where we go beyond giving just one checkpoint inhibitor, i.e. monotherapy.
In Ep 2 you’ll hear interviews conducted at the recent American Association of Immunologists (AAI) annual meeting in New Orleans.